STK11 alterations in KRAS-driven NSCLC adenocarcinomas are associated with low PD-L1 (Programmed Death-Ligand 1) levels, leading to reduced efficacy of anti-PD-1 monoclonal antibody therapy. The gene discussed is STK11; the disease is non-small cell lung carcinoma.